Fig. 8

Targeting SENP5 improved the efficacy of radiotherapy in both PDO and PDX preclinical models. A Flow chart of the establishment of PDO and PDX from clinical patients. After then the PDO and PDX were exposed to indicated doses of radiation and subjected to next experiments. B Representative images of PDO transfected with lenti-virus packaged NC or SENP5 shRNA after exposed to 8 Gy irradiation. C Quantitative analysis of organoids in different groups. **P < 0.01, *P < 0.05 Vs the NC group. D Representative images of tumors isolated from PDX bearing mice in NC and SENP5 knockdown groups at the end point of observation after local irradiation. E Growth curves were generated with tumor sizes up to day 21 post-irradiation. ***P < 0.001, *P < 0.05 Vs the NC group. F Body weight of PDX tumor bearing mice were monitored every three days. G Tumor weights were measured in different groups. H-J IHC staining and quantitative analysis of γH2AX and Ki67 positive area in tumor tissues isolated in different groups. *P < 0.05 Vs the NC group. K Hypothetical model: SENP5 promotes deSUMOylation of H2AZ to promotes its removal and the recruitment of HR repair factors, which confers cancer radioresistance